Aardvark Therapeutics, Inc. Common Stock
Follow $AARD
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AARD by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AARD moving today?
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AARD overview
Related filings and maps
Congress activity in AARD
No receipt-qualified filings found.
AARD contract awards, year to date.
Public federal awards linked to this ticker.
AARD lobbying filings, year to date.
Registered lobbying filings matched to Aardvark Therapeutics, Inc. Common Stock.
AAR CORP.
AAR CORP.
AAR CORP.